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Abstract Conventional chemotherapy is ineffective in the
majority of patients with acute myeloid leukaemia (AML),
and monoclonal antibodies recognising CD33 expressed on
myeloid progenitors (e.g. gemtuzumab ozogamicin (GO))
have been reported to improve outcome in patients with
AML. Reports of excess toxicity have resulted in GO’s licence
being withdrawn. As a result, the role of these agents remains
unclear. A systematic review and meta-analysis included stud-
ies of patients with AML who had entered a randomised
control trial (RCT), where one arm included anti-CD33 anti-
body therapy. Fixed effect meta-analysis was used, involving
calculation of observedminus expected number of events, and
variance for each endpoint in each trial, with the overall
treatment effect expressed as Peto’s odds ratio with 95 %
confidence interval. Meta-analysis of 11 RCTs with 13
randomisations involving GO was undertaken. Although GO
increased induction deaths (p=0.02), it led to a reduction in
resistant disease (p=0.0009); hence, there was no improve-
ment in complete remission.Whilst GO improved relapse-free
survival (hazard ratio (HR)=0.90, 95 % confidence interval
(CI)=0.84–0.98, p=0.01), there was no overall benefit of GO
in overall survival (OS) (HR=0.96, 95 % CI=0.90–1.02, p=
0.2). GO improved OS in patients with favourable cytogenet-
ics, with no evidence of benefit in patients with intermediate
or adverse cytogenetics (test for heterogeneity between sub-
totals p=0.01). GO has a potent clinically detectable anti-
leukaemic effect. Further trials to investigate its optimum
delivery and identification of patient populations who may
benefit are needed.
Keywords Acute myeloid leukaemia . CD33 antigen .
Systematic review .Meta-analysis . Randomised clinical
trials . Gemtuzumab .Mylotarg . Humanisedmonoclonal
antibodies
Introduction
Despite advances in supportive care, the outcome of patients
with acute myeloid leukaemia (AML) remains poor with only
about 40 % of adults under 60 years of age achieving long-
term survival, and in those over 60 years of age, less than 20%
achieve long-term survival [1]. Immunotherapeutic strategies,
utilising antibodies against tumour antigens, have proved
highly effective in other haematological malignancies [2] but
have yet to become established as standard of care in the
management of AML. CD33 is frequently expressed on the
surface of AML cells and is rarely expressed outside of the
haematological system [3]. Two anti-CD33 antibodies have
been evaluated in randomised clinical trials: lintuzumab and
gemtuzumab ozogamicin (GO, trade name, Mylotarg). GO is
a humanised monoclonal antibody against CD33, conjugated
to calicheamicin. Calicheamicin cleaves sequence-specific
DNA regions causing double-stranded breaks [4]. GO was
reported to improve overall responses dramatically in adults
with relapsed AML [5], and as a consequence, GO was given
accelerated approval by the US Food and Drug Agency in
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2000 but was subsequently voluntarily withdrawn in 2010
because of reports of excessive toxicity [6].
Given the conflicting results of different studies and the
potential importance of this drug, the aim of this systematic
review and meta-analysis is to assess the totality of the evi-
dence on the effectiveness and optimal delivery of anti-CD33
antibody treatment in AML.
Methods
Protocol and eligibility
A study protocol was drawn up prior to the review being
undertaken. We sought to include all randomised controlled
trials (RCTs) that included any patient with AML, where one
arm included anti-CD33 antibody therapy. AML could be in
any form: de novo or secondary. Previous treatment was not
an excluding factor. There were no age restrictions. We con-
sidered all examples of anti-CD33 antibody treatment, with or
without conjugation to other molecules, for example toxins.
Differing doses and regimens of the treatment did not result in
exclusion in this review.
Search strategy, sources and inclusion criteria
Searches, developed in consultation with an information spe-
cialist, were conducted in MEDLINE (1946–2013), Embase
(1974–2013) and the Cochrane Library up to December 2013.
Major conference proceedings abstracts—American Society
of Hematology (ASH) (2004–2013), European Hematology
Association (EHA) (2006–2013) and American Society of
Clinical Oncology (ASCO) (1996–2013)—were also searched
for unpublished trials. Research registers (ClinicalTrials.gov,
controlled trials.com, ISRCTN) were searched for ongoing
trials. There were no language restrictions. Search strategies
are available from the online data supplement.
Studies retrieved from the database searches were reviewed
independently by two people (JL and JK or JW), using title
and abstract to make inclusion/exclusion decisions. Full paper
copies were obtained for further review where there were
uncertainties. Disagreement regarding inclusion was re-
solved by a third member of the team (JW or JK). The
selection pathway (Fig. 1) is presented using a PRISMA
flow diagram [7].
Quality assessment and data extraction
Data was extracted by JL and JK or JW independently using a
standardised extraction form. The standardised form included
details of trial identification details, population characteristics,
details of intervention and control treatments, and outcomes.
Outcomes were defined by internationally recognised criteria
[8] and included overall survival (OS), relapse-free survival
(RFS), death in complete remission (DCR), cumulative inci-
dence of relapse (CIR), induction death (ID), resistant disease
(RD) and response. Variations in outcome definitions between
studies are outlined in the online data supplement. Toxicity data
was extracted on a standardised form (JL) and reviewed by JW.
Two reviewers (JL and JK or JW) independently assessed
each trial for risk of bias utilising the risk of bias tool devel-
oped by the Cochrane Collaboration [9].
Statistical analysis
Odds ratios (ORs) and 95 % confidence intervals (CIs) were
calculated for dichotomous outcomes. Time-to-event data was
extracted using standard methods from Tierney [10] and
Parmar [11]. Observed minus expected (O−E) number of
events and variance were calculated from hazard ratios
(HR), CIs, p values and survival proportions where available.
Fixed effect meta-analysis methods were used with the I2 test
for statistical heterogeneity performed. Tests for heterogeneity
and trend across predefined subgroups were also performed;
these subgroups included age, diagnosis, cytogenetic risk group,
FLT3-ITD, NPM1, CD33 status, stage of treatment, total cumu-
lative dose, with or without other chemotherapy agents and
treatment confounding (whether comparator arm had the same
dose of concomitant chemotherapy: yes, no). Results are present-
ed as odds ratios with 95 % CIs for dichotomous endpoints and
Peto’s odds ratios with 95 % CIs for time-to-event endpoints.
Assumptions for outcome data in studies with incomplete
reporting, taken after efforts to contact study authors, are stated
in the results.
Results
Search results
The search yielded 1974 articles (Fig. 1). A search of online
clinical trial databases suggested four pending trials. One trial
was not due for completion until January 2020 (AML SG09-09;
ClinicalTrials.gov identifier: NCT00893399) and would fit our
inclusion criteria. Another, NCRI AML17 (ISRCTN55675535),
is due to be completed July 2014. The other two were sponsored
by pharmaceutical companies; one was terminated early, and the
second did not have available data (further supplementary 5).
Two different anti-CD33 therapies were identified in this
systematic review: GO, a humanised monoclonal antibody
against CD33 conjugated to a toxin, and lintuzumab, a
humanised anti-CD33 monoclonal antibody not conjugated
to a toxin. Two trials involving lintuzumab were found [12,
13] but only one provided sufficient data for analysis of
overall survival; this study [13] did not demonstrate a signif-
icant impact of lintuzumab on overall survival (HR=0.94,
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95 % CI=0.63–1.11); however, this study was small and
underpowered. Due to their intrinsic biological differences,
these studies were omitted from the main meta-analyses that
only involved GO. Thus, 11 trials involving 13
randomisations with 7138 patients entered the meta-analysis
of trials involving GO [12–26]. A detailed summary of trials
included in this meta-analysis can be found in the supplemen-
tary data (further supplementary 4), with a brief summary of
each study described in Table 1. We also excluded two small
trials from the meta-analysis because they did not include the
same concomitant chemotherapy drugs in the GO and the
comparator arm [19, 21]. Out of the 11 trials, two had a second
independent randomisation at a latter treatment stage [17, 25].
Four studies investigated the use of GO at induction and
consolidation phases but with no independent randomisation
at the second treatment stage; therefore, these studies contrib-
uted to four randomisations only [18, 20, 26, 27]. Three
further randomisations involved the use of GO at induction
[16, 17, 25], two independent randomisations at consolidation
[17, 24] and three at a post-consolidation/maintenance stage
[22, 23, 25]. One trial used GO as part of a low-intensity
regimen [15]. Up-to-date overall survival and relapse data for
the NCRI AML15 trial was used from the AML16 publication
[16]. For one study [25], CIR and DCR were calculated from
an interim publication [28]; data from this interim analysis
was used for the induction randomisation of this study.
Risk of bias
Overall, most publications failed to describe the
randomisation and allocation method; without this informa-
tion, we are unable to assess whether these trials suffered from
selection bias. Otherwise, the risk of bias was low for the
published trials (supplementary table 1).
Two trials [26, 27] were only available in conference
proceedings form which limited assessment of risk of bias
and data extraction. Of these, one trial [27] had available data
for all outcomes, although assumptions were made for resis-
tant disease and induction death (see further supplementary 3).
The other trial [26] only provided data for OS and complete
remission (CR) rates. Although data was provided for early
deaths, it was unclear whether these deaths were induction
related or due to disease. Authors of two unpublished trials
[26, 27] were contacted to obtain full trial reports, but
1 Based on PRISMA flow diagram from: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
Fig. 1 Flow diagram of search
strategy (according to PRISMA
guidelines)
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additional data was not available for analysis. In comparison,
eight of the nine published trials [15–18, 20, 22–25] involving
GO provided complete OS data. The exception was the post-
consolidation randomisation of one trial [25]. Out of the nine
published trials involving GO, one did not provide RFS
rates for a separate consolidation randomisation [17]
(further supplementary 2).
The impact of GO on response rates and resistant disease
All induction phase trials had sufficient data for analysis of
CR rates. One non-intensive trial was omitted from this anal-
ysis because of the different treatment strategy [15]. Overall
response (OR) rates (CR plus CR with incomplete count
recovery (CRi) or platelet recovery (CRp)) were also calcu-
lated; two trial results published as abstract form did not have
sufficient data for this analysis [26, 27]. GO does not have a
measurable impact on rates of OR, CR nor CRi/p (Fig. 2 and
supplementary figure 1). However, the addition of GO to
treatment significantly reduced the rate of resistant disease
(failure to eliminate disease) by 23 % (HR=0.77, 95 % CI=
0.67–0.90, p=0.0009) (Fig. 2). However, this was at the
expense of a statistically significant increase in induction
deaths (HR=1.30, 95 % CI=1.04–1.63, p=0.02) (Fig. 2).
The impact of GO on relapse rates
GO improved CIR by 14 % (HR=0.86, 95 % CI=0.79–0.93,
p=0.0002) (Fig. 3). This is principally driven by its use in
induction treatment where the use of GO reduced the rate of
relapse by 19 % (HR=0.81, 95 % CI=0.74–0.90, p=0.00003;
test for heterogeneity between subtotals p=0.07). GO had no
significant influence on the rates of death in CR analy-
sis (HR=1.11, 95 % CI=0.91–1.36, p=0.3) (supplementary
figure 2). Thus, the improvements in CIR correlated with an
overall improvement in RFS in the overall analysis (HR=
0.90, 95 % CI=0.84–0.98, p=0.01) (Fig. 4).
GO appears to be beneficial in RFS when used as part of
remission induction therapy in a subgroup analysis based on
treatment stage (HR=0.86, 95 % CI=0.79–0.94, p=0.0007).
Although the test for heterogeneity between subtotals was
borderline (p=0.1), there is a substantial treatment effect seen
in induction subgroup. Alongside the significant result for
CIR in the setting of remission induction treatment, we ex-
plored this subgroup through predefined analyses. Subgroup
analysis did not provide clear evidence that effect size of RFS
was dependent on the age of patients (median age of trial
entrants greater or less than 60), on the cumulative dose
(greater or less than 9 mg/m2) they received and on whether
there was treatment confounding (whether or not the compar-
ative arm had the same dose of accompanying chemotherapy)
(test for heterogeneity between subtotals = not significant)
(supplementary figures 3–5).
The effect of GO on overall survival
GO had no significant effect on OS (HR=0.96, 95 % CI=
0.90–1.02, p=0.2) (Fig. 5), nor was there any evidence for a
benefit of GO at any particular treatment stage. However,
AML is a heterogeneous condition clinically and by genetic
groupings. These analyses were limited by the number of trials
involved. However, in one subgroup, there was evidence of
benefit from the use of GO in terms of OS: this was in patients
with favourable risk cytogenetics (HR=0.46, 95 % CI=0.29–
0.73, p=0.001) (test for trend between subtotals p=0.02; test
for heterogeneity between subtotals p=0.02) (Fig. 6).
GO did not improve OS, in subgroup analyses of induction
trials based on age, cumulative dose nor diagnosis (primary
vs. secondary AML) (supplementary figures 6–8). Available
data for FLT3-ITD and NPM1 analysis was limited to only
three trials and was unable to detect a significant influence of
these subgroups on OS (data not shown). A subgroup analysis
based on treatment confounding was performed (supplemen-
tary figure 9): there was some evidence of greater benefit for
the use of GO in trials without confounding chemotherapy
(test for heterogeneity p=0.09). There is no evidence that
CD33 positivity influences OS of patients treated with GO
(supplementary figure 10).
Toxicity data for GO
We investigated in detail the increased reports of liver toxicity
and incidences of severe veno-occlusive disease (VOD) [29],
particularly in the setting of haematopoietic stem cell trans-
plantation [30]. This is displayed in the supplementary data
(supplementary table 2), alongside measures of treatment-
related fatality. Data was available from four trials using
induction treatment (with some coupled with consolidation
stage), involving a total of 789 patients [18, 20, 25, 26].
Twelve cases of VOD were reported; however, there was
insufficient data available to report the incidence in the control
arm. From these trials, there were five fatalities associated
with VOD or severe hepatic toxicity when GO was used.
Three trials [16, 17, 27] did not specify the number of cases
of VOD in the GO arm but declared there were no difference
incidence by comparison of study arm. As described above,
there was a significant difference in death during induction
(Fig. 2 which was extracted from endpoints defined directly as
induction deaths [16–18, 20, 25, 27], with one omitted due to
data provided only of early deaths [26]).
Discussion
Our findings show that GO has potent anti-leukaemic effects:
there is a significant reduction in treatment-resistant disease
by 23 % (p=0.0009), but this is at the expense of an increased
Ann Hematol (2015) 94:361–373 365
induction death rate (p=0.02), leading to no improvement in
CR rates. The addition of GO to chemotherapy treatment
increases RFS by 10 % (p=0.01) by reducing the rate of
disease relapse. The reason for the reduction in relapse is
difficult to extrapolate from clinical trials, but the ALFA
0701 group has shown that patients treated with gemtuzumab
may have a deeper level of remission, as measured by NPM1
transcript levels [34].
This systematic review and meta-analysis provides a com-
prehensive synthesis of the research on the effect of the current
Trials Events/Patients
GO Control
Statistics
(O−E) Var.
O.R. & 95% CI
(GO : Control)
Resistant Disease:
Amadori, 2013 71/236 87/236 −9·8 39·5 0.78 (0.57, 1.07)
Burnett, 2011 Ind 44/556 39/557 3·1 18·9 1.18 (0.75, 1.85)
Burnett, 2012 Int 95/558 117/555 −12·7 44·2 0.75 (0.56, 1.01)
Castaigne, 2012 17/139 29/139 −6·3 10·7 0.55 (0.30, 1.01)
Delaunay, 2011 (Data not available)
Gamis, 2013 51/511 66/511 −8·0 29·2 0.76 (0.53, 1.09)
Petersdorf, 2013 Ind 44/295 60/300 −9·3 25·5 0.69 (0.47, 1.02)
Subtotal: 322/2295 398/2298 −43·0 168·0 0.77 (0.67, 0.90)
2P = 0·0009
Test for heterogeneity between trials: χ25 = 4·9; P = 0·4; NS                                                                            
Induction Death:
Amadori, 2013 40/236 28/236 6·5 17·0 1.46 (0.91, 2.35)
Burnett, 2011 Ind 39/556 33/557 2·0 17·6 1.12 (0.70, 1.79)
Burnett, 2012 Int 67/558 61/555 4·3 28·9 1.16 (0.81, 1.67)
Castaigne, 2012 9/139 5/139 2·0 3·2 1.84 (0.62, 5.50)
Delaunay, 2011 (Data not available)
Gamis, 2013 10/511 10/511 0·0 5·0 1.00 (0.42, 2.40)
Petersdorf, 2013 Ind 16/292 4/294 4·9 3·2 4.64 (1.55, 13.87)
Subtotal: 181/2292 141/2292 19·6 74·9
1.30 (1.04, 1.63)
2P = 0·02
Test for heterogeneity between trials: χ25 = 6·9; P = 0·2; NS                                                                            
Complete Response:
Amadori, 2013 86/236 97/236 5·6 28·4 1.22 (0.84, 1.76)
Burnett, 2011 Ind 456/556 462/556 2·6 40·2 1.07 (0.78, 1.45)
Burnett, 2012 Int 346/558 322/555 −11·9 68·5 0.84 (0.66, 1.07)
Castaigne, 2012 102/139 100/139 −1·0 13·9 0.93 (0.55, 1.58)
Delaunay, 2011 109/119 103/119 −3·0 5·8 0.60 (0.26, 1.35)
Gamis, 2013 450/511 434/511 −7·9 29·2 0.76 (0.53, 1.10)
Petersdorf, 2013 Ind 205/295 210/300 0·8 31·4 1.02 (0.72, 1.45)
Subtotal: 1754/2414 1728/2416 −14·8 217·4 0.93 (0.82, 1.07)
2P = 0·3; NS
Test for heterogeneity between trials: χ26 = 6·1; P = 0·4; NS                                                                            
0·0 0·5 1·0 1·5 2·0
GO Control
better better
Fig. 2 Rates of resistant death, induction death and complete remission. Forest plots (Figs. 2, 3, 4, 5, 6): black squares and horizontal lines represent
estimate and 95 % confidence interval, respectively, for each study. Open diamond represents pooled estimates for each subgroup or overall outcome
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anti-CD33 agents on all outcomes, at all treatment stages and
age. The meta-analysis of OS and RFS involved 6880 and
4366 patients, respectively. Threemeta-analyses [31–33] have
recently been published regarding the use of GO with
all three concentrating on induction treatment of AML.
One study concurs on our finding that GO improves
RFS at the expense of early mortality in induction [33]
despite the inclusion of a trial [19] that we excluded
due to the control treatment having a different concom-
itant chemotherapy regimen to the GO arm. The second
review [32] concurs with our other outcome findings in
the induction subgroup analyses (including resistant
Events/Patients
GO Control
Statistics
(O−E) Var.
O.R. & 95% CI
(GO : Control)
Induction (+/− consolidation):
Amadori, 2013 67/107 71/116 1·3 34·5 1.04 (0.74, 1.45)
Burnett, 2011 Ind 214/474 239/483 −15·9 105·5 0.86 (0.71, 1.04)
Burnett, 2012 Int 237/392 257/374 −32·5 130·7 0.78 (0.66, 0.93)
Castaigne, 2012 49/113 61/104 −11·8 27·5 0.65 (0.45, 0.95)
Delaunay, 2011 (Data not available)
Gamis, 2013 149/450 178/434 −24·1 80·0 0.74 (0.59, 0.92)
Petersdorf, 2013 Ind 60/214 61/207 −1·8 30·2 0.94 (0.66, 1.35)
Subtotal: 776/1750 867/1718 −84·8 408·4 0.81 (0.74, 0.90)
2P = 0·00003
Test for heterogeneity between trials: χ25 = 5·3; P = 0·4; NS                                                                           
Consolidation:
Burnett, 2011 Cons 184/467 204/467 −12·6 96·7 0.88 (0.72, 1.07)
Fernandez, 2011 68/138 66/132 −0·1 33·4 1.00 (0.71, 1.40)
Subtotal: 252/605 270/599 −12·7 130·1 0.91 (0.76, 1.08)
2P = 0·3; NS
Test for heterogeneity between trials: χ21 = 0·4; P = 0·5; NS                                                                           
Maintenance:
Hasle, 2012 24/59 25/61 −2·0 11·4 0.84 (0.47, 1.49)
Lowenberg, 2010 86/113 98/119 −1·7 39·4 0.96 (0.70, 1.31)
Petersdorf,2013 Post−Con 53/85 40/84 9·2 22·8 1.49 (0.99, 2.25)
Subtotal: 163/257 163/264 5·4 73·7 1.08 (0.86, 1.35)
2P = 0·5; NS
Test for heterogeneity between trials: χ22 = 3·7; P = 0·2; NS                                                                           
Non−Intensive:
Burnett, 2012 NI (Data not available)
Total: 1191/2612 1300/2581 −92·0 612·2 0.86 (0.79, 0.93)
2P = 0·0002
0·0 0·5 1·0 1·5 2·0
GO Control
better betterTest for heterogeneity (11 trials): χ210 = 14·8; P = 0·1; NS                                                                            
Test for heterogeneity between subtotals: χ22 = 5·4; P = 0·07                                                                           
Fig. 3 Cumulative incidence of relapse, grouped by treatment stage
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disease and relapse rates), notably on cytogenetic strat-
ification. In contrast to both reviews, we have included
data from more recently published trials [20, 27] which
have added data for an additional 1494 patients, includ-
ing unique data on the use of GO in induction
remission in the paediatric setting. The third meta-
analysis [31] is an individual patient data (IPD) meta-
analysis that included five induction trials [16–18, 25,
26]. This also omits the new data [20, 27] which may
be one explanation regarding the differences in
Events/Patients
GO Control
Statistics
(O−E) Var.
O.R. & 95% CI
(GO : Control)
Induction +/− consolidation:
Amadori, 2013 1/107 1/116 3·6 46·4 1.08 (0.81, 1.44)
Burnett, 2011 Ind 268/473 297/483 −19·1 137·3 0.87 (0.74, 1.03)
Burnett, 2012 Int 1/392 1/374 −24·2 139·0 0.84 (0.71, 0.99)
Castaigne, 2012 51/113 69/104 −18·6 28·5 0.52 (0.36, 0.75)
Delaunay, 2011 (Data not available)
Gamis, 2013 176/450 195/434 −15·8 92·8 0.84 (0.69, 1.03)
Petersdorf, 2013 Ind 111/205 116/210 −1·7 57·1 0.97 (0.75, 1.26)
Subtotal: 608/1740 679/1721 −76·0 501·1 0.86 (0.79, 0.94)
2P = 0·0007
Test for heterogeneity between trials: χ25 = 10·6; P = 0·06                                                                             
Consolidation:
Burnett, 2011 Cons (Data not available)
Fernandez, 2011 91/138 83/132 4·2 44·1 1.10 (0.82, 1.48)
Subtotal: 91/138 83/132 4·2 44·1 1.10 (0.82, 1.48)
2P = 0·5; NS
Maintenance:
Hasle, 2012 24/59 26/61 0·6 13·0 1.04 (0.61, 1.80)
Lowenberg, 2010 90/113 95/119 −5·7 46·2 0.88 (0.66, 1.18)
Petersdorf,2013 Post−Con 55/85 41/84 9·2 23·6 1.48 (0.99, 2.22)
Subtotal: 169/257 162/264 4·1 82·8 1.05 (0.85, 1.30)
2P = 0·7; NS
Test for heterogeneity between trials: χ22 = 4·2; P = 0·1; NS                                                                           
Non−Intensive:
Burnett, 2012 NI 65/74 34/40 2·3 22·4 1.11 (0.73, 1.68)
Subtotal: 65/74 34/40 2·3 22·4
1.11 (0.73, 1.68)
2P = 0·6; NS
Total: 933/2209 958/2157 −65·4 650·4 0.90 (0.84, 0.98)
2P = 0·01
0·0 0·5 1·0 1·5 2·0
GO Control
better betterTest for heterogeneity (11 trials): χ210 = 20·5; P = 0·02                                                                               
Test for heterogeneity between subtotals: χ23 = 5·8; P = 0·1; NS                                                                        
Fig. 4 Relapse-free survival, grouped by treatment stage
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conclusions: where in our study we find a statistically
significant increase in induction deaths, only 30-day
mortality is reported in the IPD meta-analysis from Hills
et al., and although there is a trend to favour no GO,
this was not statistically significant. Furthermore, whilst
they detect a significant improvement in OS in an
overall analysis, this is not corroborated by our system-
atic review and meta-analysis.
Deaths/Patients
GO Control
Statistics
(O−E) Var.
O.R. & 95% CI
(GO : Control)
Induction (+/− consolidation):
Amadori, 2013 210/236 204/236 19·2 105·5 1.20 (0.99, 1.45)
Burnett, 2011 Ind 314/556 340/557 −17·8 163·3 0.90 (0.77, 1.05)
Burnett, 2012 Int 376/557 408/554 −27·5 195·3 0.87 (0.75, 1.00)
Castaigne, 2012 59/139 72/139 −11·9 32·0 0.69 (0.49, 0.98)
Delaunay, 2011 56/119 64/119 −5·9 30·0 0.82 (0.57, 1.17)
Gamis, 2013 158/511 179/511 −8·1 85·8 0.91 (0.74, 1.12)
Petersdorf, 2013 Ind 151/295 142/300 9·0 73·9 1.13 (0.90, 1.42)
Subtotal: 1324/2413 1409/2416 −42·9 685·8 0.94 (0.87, 1.01)
2P = 0·1; NS
Test for heterogeneity between trials: χ26 = 14·1; P = 0·03                                                                             
Consolidation:
Burnett, 2011 Cons 166/467 160/467 1·6 80·3 1.02 (0.82, 1.27)
Fernandez, 2011 78/138 74/132 4·0 38·0 1.11 (0.81, 1.53)
Subtotal: 244/605 234/599 5·6 118·3 1.05 (0.88, 1.26)
2P = 0·6; NS
Test for heterogeneity between trials: χ21 = 0·2; P = 0·7; NS                                                                           
Maintenance:
Hasle, 2012 14/59 11/61 1·9 6·2 1.36 (0.62, 3.00)
Lowenberg, 2010 78/113 86/119 −4·1 40·9 0.90 (0.67, 1.23)
Petersdorf,2013 Post−Con (Data not available)
Subtotal: 92/172 97/180 −2·2 47·1 0.95 (0.72, 1.27)
2P = 0·7; NS
Test for heterogeneity between trials: χ21 = 0·9; P = 0·3; NS                                                                           
Non−Intensive:
Burnett, 2012 NI 229/249 228/246 −1·4 137·1 0.99 (0.84, 1.17)
Subtotal: 229/249 228/246 −1·4 137·1 0.99 (0.84, 1.17)
2P = 0·9; NS
Total: 1889/3439 1968/3441 −40·9 988·3 0.96 (0.90, 1.02)
2P = 0·2; NS
0·0 0·5 1·0 1·5 2·0
GO Control
better betterTest for heterogeneity (12 trials): χ211 = 16·5; P = 0·1; NS                                                                            
Test for heterogeneity between subtotals: χ23 = 1·4; P = 0·7; NS                                                                        
Fig. 5 Overall survival, grouped by treatment stage
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The overall effect of GO was seen only in RFS but not in
OS. GO improves OS in patients with favourable cytogenetic
AML (patients with core-binding factor translocations), with
borderline significance for those with intermediate-risk cyto-
genetics. This suggests that in the treatment of patients with
core-binding factor leukaemia, GO should become standard of
care. There was insufficient data to comment on the effect of
GO onOS in other favourable prognostic groups such as those
with NPM1 mutation. This ability to only improve survival in
favourable but not poor prognostic AML is in keeping with
Deaths/Patients
GO Control
Statistics
(O−E) Var.
O.R. & 95% CI
(GO : Control)
Favourable:
Burnett, 2011 Ind 13/72 30/65 −11·8 10·4 0.32 (0.18, 0.59)
Burnett, 2012 Int 9/18 8/14 0·0 4·2 1.00 (0.38, 2.60)
Petersdorf, 2013 Ind 5/37 11/44 −2·2 3·5 0.54 (0.19, 1.54)
Subtotal: 27/127 49/123 −14·0 18·1 0.46 (0.29, 0.73)
2P = 0·001
Test for heterogeneity between trials: χ22 = 4·0; P = 0·1; NS                                                                           
Favourable/Intermediate:
Amadori, 2013 72/87 76/96 5·0 20·8 1.27 (0.83, 1.95)
Castaigne, 2012 32/94 43/97 −5·4 10·2 0.59 (0.32, 1.09)
Subtotal: 104/181 119/193 −0·4 31·0 0.99 (0.69, 1.40)
2P = 0·9; NS
Test for heterogeneity between trials: χ21 = 4·0; P = 0·04                                                                              
Intermediate:
Burnett, 2011 Ind 154/314 174/322 −11·2 81·9 0.87 (0.70, 1.08)
Burnett, 2012 Int 194/312 219/316 −18·8 102·9 0.83 (0.69, 1.01)
Delaunay, 2011 56/119 64/119 −5·9 30·0 0.82 (0.57, 1.17)
Petersdorf, 2013 Ind 68/137 57/132 5·9 31·0 1.21 (0.85, 1.72)
Subtotal: 472/882 514/889 −30·0 245·9 0.89 (0.78, 1.00)
2P = 0·06
Test for heterogeneity between trials: χ23 = 3·6; P = 0·3; NS                                                                           
Adverse:
Amadori, 2013 38/39 32/33 −1·0 9·0 0.90 (0.47, 1.73)
Burnett, 2011 Ind 63/70 56/64 4·6 29·3 1.17 (0.81, 1.68)
Burnett, 2012 Int 85/98 100/105 −2·4 45·8 0.95 (0.71, 1.27)
Castaigne, 2012 22/28 23/30 2·2 6·1 1.43 (0.65, 3.17)
Petersdorf, 2013 Ind 41/62 39/55 −3·6 20·0 0.83 (0.54, 1.29)
Subtotal: 249/297 250/287 −0·2 110·2 1.00 (0.83, 1.20)
2P = 1·0; NS
Test for heterogeneity between trials: χ24 = 2·4; P = 0·7; NS                                                                           
unknown:
Gamis, 2013 (Data not available)
Total: 852/1487 932/1492 −44·6 405·1 0.90 (0.81, 0.99)
2P = 0·03
0·0 0·5 1·0 1·5 2·0
GO Control
better betterTest for trend between subtotals: χ21 = 5·2; P = 0·02
Test for heterogeneity between subtotals: χ23 = 9·5; P = 0·02                                                                           
Fig. 6 Overall survival, grouped by cytogenetics, for induction remission trials
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conventional chemotherapy agents, as opposed to immune-
mediated therapies, such as graft-versus-leukaemia effect in
allogeneic stem cell transplants which are effective against
adverse-risk AML [35]. One possible reason why GO might
improve RFS but not OS in the overall analysis is the presence
of salvage treatments and subsequent allogeneic
haematopoietic stem cell transplantation (HSCT) as a way of
consolidating second remissions [36].
In our predefined subgroup analysis of age, we used
60 years of age (based on the median age of trial entrants
where available) as a threshold. There is no evidence that the
benefit of GO is only restricted to younger patients. This is
notable: GO was granted early FDA approval because of
success in an older age group [5]. Furthermore, there is a
dearth of successful therapeutic options in this cohort of
patients with the outlook for elderly patients considerably
poorer than for younger patients, even when they are com-
pared in stratified cytogenetic risk groups [37]. Targeted ther-
apies may be better tolerated than conventional chemotherapy.
Below 60 years of age, our systematic review resulted in eight
randomisations at meta-analysis, only two of which was ap-
plicable in the paediatric setting [22, 27]. This is a clinical
setting for GO that deserves further attention.
Whilst there is no clear evidence that GO is not effective at
other treatment stages, the greatest amount of evidence and the
clearest evidence of benefit comes from trials in which GO
was used in induction, so we concentrated on these for the
subgroup analyses. An analysis of GO based on treatment
stage showed it is an effective adjunct in the induction treat-
ment of AML. There is currently no evidence to suggest that it
is of benefit in use at any other treatment stages; this suggests
optimisation of induction trials warrants the greatest attention.
The improvement in RFS is clearly seen when GO was used
as part of induction therapy, with improvements of 14%
(p=0.0007) detected driven by improvements in relapse rates
of 19 % (p=0.00003).
It is of particular interest to note that the trial [25] which led
to withdrawal of GO from the market had a different dose of
anthracycline (GO to no GO arm, 45 to 60 mg/m2). This stood
out on the confounding treatment subgroup analysis, whereas
those trials without a confounding treatment had an overall
improvement in OS (test for heterogeneity p=0.09). Apart
from this potential explanatory factor, there is no clear reason
for the heterogeneity observed between induction trials as
subgroup analyses did not provide any clear evidence. An
initial report of the use of GO in AML delivered a dose of
9 mg/m2 [5]. However, a considerable range in terms of both
cycle numbers and doses per cycle was seen in subsequent
trials. A recent study [18] had suggested their highly fraction-
ated protocol allowed the safe administration of a higher
cumulative dose of drug and was part of the reason why they
saw a notable benefit for GO in their trial. In contrast, in
another study, GO was delivered prior to the use of
conventional chemotherapy [20]. This difference in schedul-
ing may be a reason behind the heterogeneity between these
two studies seen in our meta-analysis notably in DCR (sup-
plementary figure 2), RFS by treatment stage (Fig. 4) and OS
by cytogenetics (Fig. 6). Our study demonstrates that sub-
groups based on cumulative doses (above and below 9 mg/
m2) did not show an advantage in OS and RFS for a higher
dose. Overall, this suggests that simple increases in the cumu-
lative dose of GO, inevitably associated with higher toxicity,
may be unnecessary.
One striking finding was that the benefit of GO was not
significantly reliant on CD33 positivity. This analysis was
limited by the fact that available published data did not pro-
vide outcome data on more detailed CD33 expression strati-
fication, and thus brought together a potentially heterogeneous
group. Publications did not detail the size of CD33+/− pre-
cursor populations, which is likely to have significant bearing
[38] on anti-CD33 treatment efficacy, as this may determine
the presence of a residual clone that may escape targeted
therapy.
The diverse settings and regimens in which anti-CD33
agents have been employed likely explain the varying results
seen with this agent, which has led to questions regarding the
overall efficacy of the treatment. There is clear evidence of the
anti-leukaemic effects of anti-CD33 therapy with GO in re-
ducing rates of resistant disease and relapse rates. There is no
significant effect on overall OS, although there was an OS
benefit, based on cytogenetic analysis, in those with
favourable core-binding factor translocations. Given the
paucity of new agents in the treatment of this condition,
this suggests this drug should not be discarded but
further trials are warranted to further optimise the de-
livery of this drug to allow more patients with AML to
benefit from this treatment.
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